GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

Bayer Schering Pharma Contracts Dyax to Discover Therapeutic mAbs

  • Dyax inked an agreement with Bayer Schering Pharma for the discovery of therapeutic antibodies. Bayer Schering Pharma will provide two targets, and Dyax will identify related antibodies.

    Dyax will receive milestone payments and royalties. The deal also provides Bayer Schering Pharma with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax' technology.

    These research activities may be expanded to allow Dyax to work on additional targets and/or allow Bayer Schering Pharma to exercise an option for an antibody library license.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »